[Analysis of whole blood cells and genetic influencing factors in medical radiation workers].

Objective: To explore the influencing factors of whole blood cells and genetics of medical radiation workers, and provide technical support for improving occupational health management and strengthening radiation protection. Methods: In January 2022, a total of 4180 medical radiation workers who underwent occupational health examination in Gansu Provincial Center for Disease Control and Prevention from January 2020 to December 2021 were collected as the research objects, and the results of demographic characteristics, whole blood cells, chromosome aberrations, lymphocyte micronucleus and other results were collected. The whole blood cells and genetic abnormalities of different demographic characteristics of medical radiation workers were compared. And the influencing factors of whole blood cells and genetic abnormalities were analyzed by multivariate logistic regression. Results: The rates of hemoglobin (HGB), chromosome aberration and lymphocyte micronucleus abnormality were the highest in the nuclear medicine group, and the rate of white blood cell (WBC) abnormality in the radiotherapy group was higher than those in other occupational groups, the differences were statistically significant (P<0.05). The abnormal rates of WBC, HGB and lymphocyte micronucleus in female radiation workers were significantly higher than those in male radiation workers (P<0.001). The abnormal rates of HGB and lymphocyte micronucleus were statistically different among different working years and different age radiation workers (P<0.001). And the abnormal rate of platelet (PLT) was statistically different among different working years radiation workers (P<0.05). The abnormal rate of HGB in radiation workers of different hospital levels was statistically different (P<0.001). Logistic regression analysis showed that the risk of abnormal WBC and HGB in females radiation workers were 3.048 times and 13.122 times of those in males, respectively (P<0.001). The abnormal risks of WBC in the 6-20 working years group and >20 working years group were 1.517 times and 1.874 times of that in the ≤5 working years group, respectively (P<0.05). The abnormal risk of PLT in the >20 working years group was 2.643 times of that in ≤5 working years group (P<0.05). The abnormal risk of WBC in radiotherapy group and intervention group were 2.407 times and 1.341 times of that in general radiotherapy group, respectively (P<0.05) . Conclusion: Ionizing radiation has different effects on the whole blood cells and genetic indexes of workers in the nuclear medicine, interventional group and radiotherapy group. The occupational health protection of female radiation workers should be paid attention to.

[Effect of progesterone receptor status on efficacy of aromatase inhibitors and survival time in patients with advanced breast cancer].

To investigate the effect of progesterone receptor (PR) on the efficacy of first-line aromatase inhibitor (AI) endocrine therapy and progression-free survival (PFS) in patients with estrogen receptor (ER) positive HER-2 negative advanced breast cancer. The clinical data of 198 patients with advanced breast cancer treated in Henan Cancer Hospital from January 2014 to October 2019 were collected. The Chi-square test was used to compare the difference between the two groups, and the Cox regression model was used to analyze the related prognostic factors. The median progression-free survival time ((PFS)) of PR+and PR- patients were 12.5 months and 9.0 months, respectively, and the difference was statistically significant (P=0.004). The clinical benefit rate (CBR) was 81.1% and 63.1%, respectively, and the difference was not statistically significant (P<0.001). PR is an independent prognostic factor of first-line AI endocrine therapy in ER-positive HER-2-negative patients. PR+type breast cancer has a better response to first-line AI endocrine therapy and longer PFS time than PR- type advanced breast cancer.

[Clinical observation of palbociclib combined with endocrine therapy in hormone receptor positive and HER2 negative advanced breast cancer].

Objective: To analyze the application, efficacy, and safety of palbociclib in hormone receptor positive (HR+) and HER2 negative (HER2-) advanced breast cancer in the real world. Methods: The information of patients who received palbociclib treatment from September 2018 to September 2020 was collected, and the general medical history data and disease characteristics were summarized. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), time to treatment failure (TTF), and safety were analyzed. Results: A total of 55 patients with HR+/HER2-advanced breast cancer who received a treatment regimen containing palbociclib were enrolled. The ORR was 48.8%, and DCR was 88.4%. The median PFS was 12.0 months (95%CI, 11.1-13.0 months), and the median TTF was 8.50 months (95%CI, 2.5-14.5 months). Among them, palbociclib was superior to multi-line therapy in the first line (P=0.000 1). The prognosis of patients with non-liver metastases was better (P=0.01). Hematological toxicity was the focus of observation of adverse events, including leukopenia, neutropenia, and thrombocytopenia. The incidence rates of them were 78.2%, 85.5%, and 34.5%, respectively. No other grade 3-4 nonhematological toxicity was found. Conclusions: Palbociclib combined with endocrine therapy in patients with HR+/HER2-advanced breast cancer has good efficacy and controllable adverse reactions. It can be used as a first-line or multi-line treatment option for HR+/HER2-advanced breast cancer.

[Clinical observation of apatinib mesylate for the treatment of multi-drug resistant advanced breast cancer].

Objective: To assess the clinical efficacy and adverse outcomes of apatinib mesylate for the treatment of multi-drug resistant advanced breast cancer. Methods: A total of 24 patients with multi-drug-resistant advanced breast cancer who underwent apatinib mesylate treatment were retrospectively analyzed at the Diagnosis and Treatment Center for Breast Cancer of Henan Cancer Hospital. Patients were reviewed every 4 weeks after initial treatment and then every 8 weeks after stable disease. Objective response rate (ORR), progression free survival (PFS), overall survival (OS) , toxicity and adverse outcomes of apatinib mesylate treatment were evaluated by imaging examinations. Results: Totally, 24 patients received apatinib mesylate at a dose of 500 mg QD. Out of the 24 patients treated, complete remission (CR) occurred in none of the patients, partial remission (PR) in 10 cases, stable disease (SD) in 10 cases, progressive disease (PD) in 4 cases, and drug with drawal in 2 cases due to adverse outcomes. Treatment with apatinib mesylate resulted in an ORR of 41.7% (10/24), disease control rate (DCR) of 83.3%, PFS of 4.7 months, and OS of 8.0 months. Adverse outcomes included proteinuria, high blood pressure, fatigue, hand-foot skin reaction (HFSR), hyperbilirubinemia, leukopenia, hair/skin pigmentation decreased. Most of the adverse events were tolerable and can be controlled after symptomatic management. Conclusions: Single-agent apatinib mesylate demonstrated the good short-term efficacy for multi-drug resistant advanced breast cancer in patients who previously underwent multiple line treatment failures. Adverse effects were controllable after symptomatic management. Treatment with apatinib mesylate maybe a viable option when other treatment modalities failed.

[Occupational health status about radiation workers from township hospitals in Gansu, China].

Objective: To investigate occupational health status about radiation workers from township hospitals in Gansu, China, and to explore the dose-effect relationship of exposure dose of radiation workers. Methods: A total of 390 X-ray workers from township hospitals in Gansu Province and 450 X-ray workers from the county/district-level hospitals in the county/district where the township hospitals were located were divided into research group and control group. Their workload, radiation protection condition, and occupational health monitoring data were used for impact assessment and risk estimation. Results: The annual workload of radiation workers from township hospitals was 845.33±361.622 people, and that of radiation workers from county/district-level hospitals was 1967.74±762.055 people; there was a significant difference in annual workload between the two groups of subjects (P<0.05) . Indices such as detection rate of lens opacity, detection rate of abnormal platelet count, red blood cell count, and hemoglobin count, micronucleated lymphocyte rate, and chromosome aberration rate were significantly different between the two groups (P<0.05) . Conclusion: Radiation workers from township hospitals suffer from certain radiation damage.

Activin A as a novel biomarker for colorectal adenocarcinoma in humans.

OBJECTIVE: Early diagnostics of colorectal cancer is complicated by the lack of reliable serum biomarkers. This study aimed to investigate if the serum level of activin A can be used for diagnostics of this disease. PATIENTS AND METHODS: In this study we measured the level of activin A in patients with colorectal adenocarcinoma, benign colorectal polyps, as well as in healthy subjects. RESULTS: We found that the level of activin A was significantly higher in patients with colorectal adenocarcinoma, as compared to patients with polyps and healthy controls. Furthermore, activin A levels correlated well with the stage of colorectal cancer. The level of activin A was substantially reduced in post-operative patients. Immunohistochemical staining demonstrated that high levels of activin A were present in the adenocarcinoma tissue samples but not in the non-cancerous samples. RT-PCR further confirmed that mRNA of ßA subunit of activin A is significantly over-expressed in the majority of cancerous samples. Western blotting results further demonstrated the elevated level of activin A in cancer samples. CONCLUSIONS: Taken together, the findings suggest that colorectal adenocarcinomas directly secret activin A into the blood stream. Measuring the serum level of activin A might be used as a reliable diagnostic and screening tool in clinical practice.

Odorant-binding protein (OBP) genes affect host specificity in a fig-pollinator mutualistic system.

The interaction between figs and their pollinating wasps is regarded as a model system for studying specialized co-evolved mutualism. Chemoreception of fig wasps plays an important role in this interaction, and odorant-binding proteins (OBP) function in the first step of odorant detection. The OBP repertoire of the fig wasp Ceratosolen solmsi is reported to be one of the smallest among insects; however, it is unknown how these OBPs are related to the complicated mating process occurring within the fig cavity and the extreme host specificity of the species. In the present study, we combined a structural analysis of the conserved cysteine pattern and motif order, a phylogenetic analysis, and previous studies on ligand-binding assays to deduce the function of OBPs. We also quantified the expression of OBP genes in different life stages of female and male fig wasps by using real-time quantitative PCR, which can help to predict the function of these genes. The results indicated that CsolOBP1 and CsolOBP2 (or CsolOBP5) in males may bind to pheromones and play important roles in mate choice, whereas CsolOBP4 and CsolOBP5 may primarily function in host localization by females through binding of volatile compounds emitted by receptive figs.